Collegium Pharma (COLL) Tops Q2 EPS by $1.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million
August 5, 2021 4:01 PM EDTXtampza® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021
Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million
Full-Year 2021 Product Revenue Guidance Updated
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty... More
